{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:54:07Z","timestamp":1760151247656,"version":"build-2065373602"},"reference-count":14,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent 18F-Fluorodeoxyglucose ([18F]FDG) positron-emission tomography\/computed tomography (PET\/CT) pre- and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Post-therapeutic [18F]FDG PET\/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient\u2019s symptoms and decrease in serum tryptase level. [18F]FDG PET\/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis.<\/jats:p>","DOI":"10.3390\/diagnostics12030680","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:46:47Z","timestamp":1646912807000},"page":"680","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Mastocytosis Treatment with Midostaurin: [18F]FDG PET\/CT as a Potential Monitoring Tool for Therapy Outcome"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-8860","authenticated-orcid":false,"given":"Caroline","family":"Burgard","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, 66421 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-4099","authenticated-orcid":false,"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, 66421 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-7477","authenticated-orcid":false,"given":"Fadi","family":"Khreish","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, 66421 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-3375","authenticated-orcid":false,"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saarland University, 66421 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive Systemic Mastocytosis and Related Mast Cell Disorders: Current Treatment Options and Proposed Response Criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"ref_3","first-page":"1572","article-title":"Systemic mastocytosis","volume":"139","author":"Metzgeroth","year":"2014","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT Mutation in Mast Cells and Other Bone Marrow Hematopoietic Cell Lineages in Systemic Mast Cell Disorders: A Prospective Study of the Spanish Network on Mastocytosis (REMA) in a Series of 113 Patients","volume":"108","author":"Teodosio","year":"2006","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time QPCR Assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12288-020-01279-8","article-title":"The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis","volume":"36","author":"Helbig","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_7","first-page":"68950","article-title":"Imatinib in Systemic Mastocytosis: A Phase IV Clinical Trial in Patients Lacking Exon 17 KIT Mutations and Review of the Literature","volume":"8","author":"Matito","year":"2016","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and Safety of Midostaurin in Patients with Advanced Systemic Mastocytosis: 10-Year Median Follow-up of a Phase II Trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Szudy-Szczyrek, A., Bachanek-Mitura, O., Gromek, T., Chromik, K., Mital, A., Szczyrek, M., Krupski, W., Szumi\u0142o, J., Kandu\u0142a, Z., and Helbig, G. (2021). Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051109"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00259-015-3117-3","article-title":"FDG-PET\/CT Findings in Systemic Mastocytosis: A French Multicentre Study","volume":"42","author":"Chandesris","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/RLU.0b013e3181638e5e","article-title":"Imaging of Systemic Mastocytosis by FDG-PET\/CT Demonstrates Increased Activity in Cortical Bone","volume":"33","author":"Tomihama","year":"2008","journal-title":"Clin. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2214\/ajr.179.5.1791235","article-title":"FDG Positron Emission Tomography in Patients with Systemic Mastocytosis","volume":"179","author":"Zettinig","year":"2002","journal-title":"Am. J. Roentgenol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/a-1650-9704","article-title":"Aggressive Systemic Mastocytosis with Diffuse Bone Marrow 18F-FDG Uptake","volume":"61","author":"Doubek","year":"2022","journal-title":"Nuklearmedizin"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/3\/680\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:34:22Z","timestamp":1760135662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/3\/680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["diagnostics12030680"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12030680","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}